Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Sci Transl Med. 2011 May 18;3(83):83ps19. doi: 10.1126/scitranslmed.3001819.
Immune-suppressive cellular immunotherapy requires large numbers of antigen-specific regulatory T cells (T(reg) cells), lymphocytes that suppress certain immune responses. Together, three papers in this issue of Science Translational Medicine describe protocols for the ex vivo expansion of human T(reg) cells and assess the immune-suppressive function of ex vivo-manipulated T(reg) cells after transfer into humanized mouse disease models. Along with recent phase I clinical trial results, these new data provide a platform for clinical use of T(reg) cells as personalized therapeutic agents for the treatment of autoimmune diseases, graft-versus-host disease, and transplant rejection.
免疫抑制性细胞免疫疗法需要大量的抗原特异性调节性 T 细胞（Treg 细胞），即抑制某些免疫反应的淋巴细胞。本期《科学转化医学》中的三篇论文共同描述了体外扩增人 Treg 细胞的方案，并评估了在人源化小鼠疾病模型中转移后体外操作的 Treg 细胞的免疫抑制功能。这些新数据与最近的 I 期临床试验结果一起，为 Treg 细胞作为治疗自身免疫性疾病、移植物抗宿主病和移植排斥的个体化治疗药物的临床应用提供了平台。
